Cargando…

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()

SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory res...

Descripción completa

Detalles Bibliográficos
Autores principales: Figuero-Pérez, Luis, Olivares-Hernández, Alejandro, Escala-Cornejo, Roberto A., Terán-Brage, Eduardo, López-Gutiérrez, Álvaro, Cruz-Hernández, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561306/
https://www.ncbi.nlm.nih.gov/pubmed/34823820
http://dx.doi.org/10.1016/j.reumae.2020.06.008
_version_ 1783595242341007360
author Figuero-Pérez, Luis
Olivares-Hernández, Alejandro
Escala-Cornejo, Roberto A.
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Cruz-Hernández, Juan J.
author_facet Figuero-Pérez, Luis
Olivares-Hernández, Alejandro
Escala-Cornejo, Roberto A.
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Cruz-Hernández, Juan J.
author_sort Figuero-Pérez, Luis
collection PubMed
description SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra).
format Online
Article
Text
id pubmed-7561306
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
record_format MEDLINE/PubMed
spelling pubmed-75613062020-10-16 Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab() Figuero-Pérez, Luis Olivares-Hernández, Alejandro Escala-Cornejo, Roberto A. Terán-Brage, Eduardo López-Gutiérrez, Álvaro Cruz-Hernández, Juan J. Reumatol Clin (Engl Ed) Special Article SARS-CoV-2 is a new RNA virus which causes coronavirus disease 2019 (COVID-19), declared a pandemic by the World Health Organization (WHO). It triggers an atypical pneumonia that can progress to multiorgan failure. COVID-19 can cause dysregulation of the immune system, triggering an inflammatory response, and simulate haemophagocytic lymphohistiocytosis. Several studies have proposed that anti-IL-6 receptor antibodies, such as tocilizumab, play an important role in the treatment of severe acute respiratory infection associated with SARS-CoV-2. However, the role of anti-IL-1 receptor antibodies, such as anakinra, in the treatment of COVID-19 has not been established. We present a case report of a 51-year-old man diagnosed with severe respiratory infection associated with SARS-CoV-2 that was refractory to antiviral and anti-IL-6 treatment, with a favourable clinical outcome and analytical improvement after treatment with anti-IL-1 (anakinra). Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2021-12 2020-10-15 /pmc/articles/PMC7561306/ /pubmed/34823820 http://dx.doi.org/10.1016/j.reumae.2020.06.008 Text en © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Special Article
Figuero-Pérez, Luis
Olivares-Hernández, Alejandro
Escala-Cornejo, Roberto A.
Terán-Brage, Eduardo
López-Gutiérrez, Álvaro
Cruz-Hernández, Juan J.
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title_full Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title_fullStr Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title_full_unstemmed Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title_short Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
title_sort anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with sars-cov-2 refractory to tocilizumab()
topic Special Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561306/
https://www.ncbi.nlm.nih.gov/pubmed/34823820
http://dx.doi.org/10.1016/j.reumae.2020.06.008
work_keys_str_mv AT figueroperezluis anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab
AT olivareshernandezalejandro anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab
AT escalacornejorobertoa anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab
AT teranbrageeduardo anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab
AT lopezgutierrezalvaro anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab
AT cruzhernandezjuanj anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumab